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In spite of its long demonstrated potential, microbeam radiosurgery (MBRS) has yet to be developed into
a clinical tool. This article examines the problems associated with MBRS, and potential solutions. It is
shown that a path to a clinically useful device is emerging.
© 2015 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In conventional radiotherapy, the ability to destroy a cancerous
tumor is limited by normal tissue toxicity. Typically, a total dose
between 50 and 100 Gy is delivered to malignant tissue. While
higher doses would certainly lead to greater tumor control, such
higher doses are not possible because of damage to surrounding
healthy tissue.
A number of scientiﬁc studies on small animals over the past
two decades have demonstrated the astonishing fact that healthy
tissue can tolerate an enormous amount of dose (>300 Gy) when
delivered in small diameter beams or thin planes of radiation
(<700 mm), termed microbeam radiation [1e5]. Although cells in
the direct paths of the microbeams are killed, the adjacent non-
irradiated tissues mount a healing response. Studies have also
demonstrated that malignant tissue can be destroyed by micro-
beam radiation via cross-ﬁring from several directions [5e8]. Thus,
MBRS appears to have tremendous potential to control internal
disease with little or no toxicity to surrounding healthy tissue.
In spite of its extraordinary potential, MBRS has yet to become
available to the clinic. The problems which have kept MBRS from
the clinic, along with potential solutions, are examined herein.ica. Published by Elsevier Ltd. ThisDiscussion
From an industrial perspective, there are ﬁve major problems
associated with the current state-of-the-art of MBRS. These are use
case, photon energy, targeting method, radiation source, and
biology. Each of these problems is discussed below.Use case
Although several small animal models have been used (mice,
rats, rabbits, and piglets), nearly all pre-clinical MBRS studies to
date have focused on brain tissue. While a device that would cure
brain cancer is greatly desired, such a device would command a
small market from the perspective of an industrial manufacturer of
radiotherapy equipment. Cancer statistics for the USA in the year
2013 show that brain cancers accounted for 1.4% of all cancers [9].
See Fig. 1. To warrant the long and expensive route of product
development, it is necessary to show that MBRS is effective in
destroying many more types of malignant tissue while still sparing
the corresponding many more types of healthy tissue.
For conventional radiotherapy, lung cancer is a large (14% of all
cancers) but woefully underserved market because radiation often
induces pulmonary ﬁbrosis. Pulmonary ﬁbrosis alone can lead to
death. Recently, Varian Medical Systems, Inc. (USA), in collabora-
tion with the European Synchrotron Radiation Facility (France),
launched a study to determinewhether or notmicrobeam radiation
induces ﬁbrosis in the lungs of rats. The results of this study are
pending, and will be reported at a later date.is an open access article under the CC BY-NC-ND license (http://creativecommons.
Figure 1. Distribution of cancers, by anatomical site, presented in the USA during the
year 2013.
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respectfully called upon to explore the effects of microbeam radi-
ation on yet more types of tissue and cancers; e.g., liver, pancreas,
kidney, bladder, etc.Photon energy
All MBRS studies have employed spectra of low energy photons
which peak between 50 and 150 keV. While such photon energies
are sufﬁcient for small animals, they are not sufﬁcient to provide
dose at depth in human patients. Figure 2 shows the percentageFigure 2. Calculated percentage depth dose curves for 500 mm diamedepth dose curves for 500 mm diameter pencil beams of mono-
chromatic 200 keV and 2 MeV photons. At 20 cm depth, which is
half-way into the wide portions of a human patient, 200 keV
photons supply only 5% of incident dose. The lower energy photons
used in MBRS provide even less. 2 MeV photons, such as used in
conventional radiotherapy, provide 35% of incident dose at 20 cm
depth.
Figure 2 also shows that peak dose deposition for low energy
photons occurs at the surface of the patient; i.e., at the skin. This is
important because there are many nerve endings in skin, and
damage to the skin is very painful. Even though damage created by
microbeams at the skin may be expected to heal nicely, such
damage will likely be painful during the healing process. Peak dose
deposition for high energy photons, however, occurs below the
skin, allowing for pain-free experience.
The primary reason low energy photons have been used in
MBRS studies up to now is that it has been the thinking of re-
searchers in the ﬁeld that the lateral dose deposition proﬁle (i.e., in
the direction orthogonal to the direction of beam propagation)
must have a square wave shape [4]. That is, the dose in the valley
regions of the microbeam array must be low and ﬂat, the dose in
the peak regions must be high and ﬂat, and the transition between
the two regions must be sharp. This dose proﬁle assures that there
is no damage to healthy tissue in the valley regions, thereby
allowing such undamaged tissue to provide a healing response to
the destruction generated in the peak regions. Because of the
phenomenon of Compton scattering, high energy photons yield a
rounded lateral dose deposition proﬁle. Figure 3 shows the lateral
dose deposition proﬁles for 500 mm diameter pencil beams of
200 keV and 2 MeV photons. The 2 MeV photon case clearly does
not meet the squarewave proﬁle requirement. Because of dose tails
extending into the valley regions, microbeams with photon en-
ergies above 200 keV have been considered unacceptable.
With this article, a shift in thinking is proposed. It is herein
argued that the shape of the lateral dose deposition proﬁle is
immaterial. Rather, what is important is that the biological damage
zone created by a microbeam be sufﬁciently narrow that the un-
damaged regions on either side are able to induce healing. It is
proposed that the Compton scattering of high energy photons beter microbeams of monochromatic 200 keV and 2 MeV photons.
Figure 3. Calculated percentage lateral dose proﬁles for 500 mm diameter microbeams. The green curve is the incident and ideal proﬁle on a patient. The blue curve is the proﬁle for
200 keV monochromatic photons 500 mm deep into the patient. The red curve is the proﬁle for 2 MeV monochromatic photons 500 mm deep into the patient.
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beam. The incident width must be chosen such that the peak and
tail regions of the dose deposition proﬁle create a biological dam-
age zone which can be healed. Figure 4 graphically portrays this
new approach. If the biological damage zone created by the square
wave dose deposition proﬁle is capable of being healed, then clearly
so is the biological damage zone created by the rounded dose
deposition proﬁle.
It must be noted at this juncture that the peak plus tail regions
for microbeam photons in the MeV energy range are quite large.Figure 4. Schematic of the biological damage zone concept.Monte Carlo calculations show that for a 100 mm diameter incident
microbeam of 2 MeV photons, the tail falls below 10% of the peak at
a diameter of 400 mm. This implies relatively large biological
damage zones. Studies have shown, however, that microbeam
widths as large as 700 mm perform satisfactorily [6].
The utility of microbeams at higher energies than currently used
must be explored experimentally. If it cannot be shown that sig-
niﬁcant dose can be deposited at depth while also avoiding painful
skin damage, it is unlikely that microbeam radiosurgery will be
clinically useful.Targeting method
The most successful microbeam targeting technique employed
to date for the destruction of diseased tissue involves the inter-
lacing of microbeam arrays ﬁred from several ports [6,7]. See Fig. 5.
This technique creates a broad beam dose proﬁle at the target, as
does conventional radiotherapy. It is reasonable to presume that
with this targeting technique, a malignant tumor may be controlled
as well as, and in accordance with, conventional radiotherapy
dosing protocols.
Patient motion, however, presents a serious problem for the
interlacing technique. It is anticipated that a clinical device will
deliver the microbeam arrays associated with each port sequen-
tially in time. (A device that would have several radiation sources,
allowing for simultaneous delivery of microbeam arrays from all
ports, would be cost prohibitive.) In transitioning from one port to
the next, either the microbeam radiation source (preferred) or the
patient will be repositioned. If patient registration relative to the
microbeam tracks from any port is lost during the repositioning
procedure, the interlacing of damaged regions at the target will not
occur properly, and a broad beam damage pattern will not be
achieved. Patient motion on the order of a single microbeamwidth
will compromise the effectiveness of the interlacing technique.
Patient motion larger than this is guaranteed in practice.
It is helpful now to recall what studies have revealed regarding
the biology associated with microbeams. With regard to the
Figure 5. The interlacing targeting technique. (a) Microbeam arrays directed toward
the target. (b) Microbeam arrays at the intersection with the target. (c) Cross section
through the microbeam arrays and the target.
Figure 6. The dicing targeting technique. (a) Microbeam arrays directed toward the
target. (b) Microbeam arrays at the intersection with the target. (c) Cross section
through the microbeam arrays and the target.
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ered so far indicates that differences in the microvasculature of
tumors and normal tissue are responsible. The blood vessels of
tumors are faster growing and immature, larger in diameter, fewer
in density, and more tortuous in shape than the blood vessels of
normal tissue. The tumor blood vessels damaged by microbeams
are unable to repair, whereas the normal tissue blood vessels heal
[10e12].Given the knowledge of the effect of microbeams on microvas-
culature, it is herein proposed that a dicing technique rather than an
interlacing technique be used to destroy malignant tissue. See
Fig. 6. Each plane of microbeam radiation will destroy the tumor
blood vessels in its path. By arranging the planes of microbeam
radiation to dice the target tissue into small volumes, the blood
supply to these small volumes of tissue will be cut off. The tumor
will die by way of ischemia.
Figure 7. Inverse Compton scattering.
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bearing rats [8]. However, radiation from each of the three ports
was not delivered in the same treatment session. Radiation de-
liveries from the second and third ports were 24 and 48 h after the
ﬁrst, respectively. Although survival times increased signiﬁcantly
for the irradiated animals, histological investigation showed that
the tumors were not ablated. For the proposed dicing technique to
work, radiation from all ports must be delivered in the same
treatment session.
Note that the dicing targeting method is insensitive to patient
motion during the repositioning procedure between ports.
Further studies on the dicing targeting technique are warranted.
Radiation source
The most daunting obstacle standing between MBRS and the
clinic is the radiation source. Presently, effective microbeam arrays
can be generated only by synchrotron sources. A synchrotron isFigure 8. An inverse Compton scattering X-ray source, tunable from 10 to 35required for low beam divergence and high dose rate. The low beam
divergence is necessary to keep the microbeams from spreading to
larger widths as they pass through a patient. The high dose rate is
required so that patient motion during microbeam delivery does
not broaden the damage region. Unfortunately, synchrotrons are
very large devices with construction and operation costs at levels
that only nation states can provide.
Several groups around the world are working to develop a new
type of radiation source that employs inverse Compton scattering
(ICS) [13e15]. Figure 7 displays the ICS process in which a high
energy electron collides with a low energy photon to yield a high
energy photon and a reduced energy electron. First generation ICS
sources are expected to produce radiation very similar to that of
synchrotron radiation, with the exception of dose rate. Later gen-
erations of ICS sources are expected to match the dose rate of
synchrotrons. ICS sources are expected to be a few meters in
diameter, rather than the kilometer diameter typical of synchro-
trons. Also, ICS sources are expected to cost about as much as to-
day's linear accelerators used in conventional radiotherapy.
Figure 8 shows a ﬁrst generation ICS source developed at Lyncean
Technologies located in Palo Alto, California, USA.
A small footprint, low cost alternative to the synchrotron, such
as an ICS source, must be developed if MBRS is to become a clinical
tool.
Biology
Further elucidation of the biological underpinnings of MBRS is
needed. Two fundamental biology questions should be answered.
First, how is a cell killed by the extremely high doses delivered
byMBRS? In conventional fractionated radiotherapy, a dose of 2 Gy
is delivered per fraction. It is understood that cell death occurs by
reason of radiation induced DNA damage and subsequent mitotic
catastrophe [16]. In conventional hypo-fractionated radiosurgery, a
dose of 7e25 Gy is delivered per fraction. There is evidence that
intrinsic apoptosis is induced at the higher end of that dose range
[17,18]. The dose regime of MBRS so far exceeds current practice
that the kill mechanism comes into question. Do cells die bymitotic
catastrophe, intrinsic apoptosis, regulated necrosis, autophagy, or akeV. (Courtesy of Lyncean Technologies, Inc., Palo Alto, California, USA.)
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be a more physical mechanism? Could purely physical damage to
the stroma of the cells be the cause of death?
The second fundamental biology question which must be
answered is themore important. How is normal tissue destroyed by
microbeams “healed” by adjacent non-irradiated tissue? This is the
most surprising feature of MBRS. In conventional broad beam
radiotherapy, healing of normal tissue irradiated with doses above
2 Gy does not occur. The response of normal tissue tomicrobeams is
the breath-taking feature which motivates industrial interest. Yet,
this feature is not at all understood. The subject of macroscopic
wound healing has been studied extensively over many years
[20,21]. The processes involved are complicated, with events
happening on molecular, cellular, and tissular levels, over time
frames of minutes, hours, days, weeks, and months. Are the same
processes involved for microscopic radiation-induced wounds?
Although it is not necessary to answer these fundamental
biology questions completely before making use of MBRS in the
clinic, further understanding of the biological processes involved
will most certainly lead to better treatments.
Conclusions
Although signiﬁcant obstacles must be overcome, it appears
possible to bring MBRS into the clinic. It is hoped that this article
will spur scientiﬁc researchers and product developers alike to
address the issues raised. It is hoped that the extraordinary po-
tential of MBRS to ﬁght the insidious disease of cancer may be
realized.
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